{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:52:23Z","timestamp":1775620343460,"version":"3.50.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s43032-025-01948-x","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T12:40:04Z","timestamp":1755261604000},"page":"2842-2863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches"],"prefix":"10.1007","volume":"32","author":[{"given":"Meeral","family":"Gosia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhi","family":"Parab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-8943","authenticated-orcid":false,"given":"Angel","family":"Godad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"crossref","unstructured":"Mhatre A, Koroth J, Manjunath M, Kumar SS, Gawari R, Choudhary B. Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns. Front Genet. 2023;14:1234567","DOI":"10.3389\/fgene.2023.1102114"},{"key":"1948_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1201\/9780429053016-15","volume-title":"Muir\u2019s textbook of pathology","author":"CS Herrington","year":"2020","unstructured":"Herrington CS. The female reproductive system. In: Herrington CS, editor. Muir\u2019s textbook of pathology. 16th ed. Boca Raton, FL: CRC Press; 2020. p. 405\u201326.","edition":"16"},{"key":"1948_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih I-M. The dualistic model of ovarian carcinogenesis. Am J Pathol. 2016;186:733\u201347.","journal-title":"Am J Pathol"},{"key":"1948_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1089\/omi.2017.0115","volume":"21","author":"E Gov","year":"2017","unstructured":"Gov E, Kori M, Arga KY. Multiomics analysis of tumor microenvironment reveals gata2 and miRNA-124-3p as potential novel biomarkers in ovarian cancer. OMICS. 2017;21:603\u201315.","journal-title":"OMICS"},{"key":"1948_CR5","doi-asserted-by":"crossref","unstructured":"Bullock B, Larkin L, Turker L, Stampler K. Management of the adnexal mass: considerations for the family medicine physician. Front Med (Lausanne). 2022;9:913549.","DOI":"10.3389\/fmed.2022.913549"},{"key":"1948_CR6","doi-asserted-by":"crossref","unstructured":"Bhadra M, Sachan M, Nara S. Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool. Front Mol Biosci. 2024;11:1361601.","DOI":"10.3389\/fmolb.2024.1361601"},{"key":"1948_CR7","doi-asserted-by":"crossref","unstructured":"Wang Y, Kim S, Kim I. Regulation of metastasis by microRNAs in ovarian cancer. Front Oncol. 2014;4:143.","DOI":"10.3389\/fonc.2014.00143"},{"key":"1948_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/AOG.0000000000005211","volume":"142","author":"W Burke","year":"2023","unstructured":"Burke W, Barkley J, Barrows E, Brooks R, Gecsi K, Huber-Keener K, et al. Executive summary of the ovarian cancer evidence review conference. Obstet Gynecol. 2023;142:179\u201395.","journal-title":"Obstet Gynecol"},{"key":"1948_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1021\/pr500908n","volume":"14","author":"KS Anderson","year":"2015","unstructured":"Anderson KS, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, et al. Autoantibody signature for the serologic detection of ovarian cancer. J Proteome Res. 2015;14:578\u201386.","journal-title":"J Proteome Res"},{"key":"1948_CR10","doi-asserted-by":"publisher","first-page":"188584","DOI":"10.1016\/j.bbcan.2021.188584","volume":"1876","author":"AV Zamaraev","year":"2021","unstructured":"Zamaraev AV, Volik PI, Sukhikh GT, Kopeina GS, Zhivotovsky B. Long non-coding RNAs: a view to kill ovarian cancer. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 2021;1876:188584.","journal-title":"Biochimica et Biophysica Acta (BBA) - Rev Cancer"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.4049\/jimmunol.1103175","volume":"188","author":"FF Kirigin","year":"2012","unstructured":"Kirigin FF, Lindstedt K, Sellars M, Ciofani M, Low SL, Jones L, et al. Dynamic MicroRNA gene transcription and processing during T cell development. J Immunol. 2012;188:3257\u201367.","journal-title":"J Immunol"},{"key":"1948_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1261\/rna.041814.113","volume":"20","author":"P Ramalingam","year":"2014","unstructured":"Ramalingam P, Palanichamy JK, Singh A, Das P, Bhagat M, Kassab MA, et al. Biogenesis of intronic miRNAs located in clusters by independent transcription and alternative splicing. RNA. 2014;20:76\u201387.","journal-title":"RNA"},{"key":"1948_CR13","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00018-016-2174-5","volume":"73","author":"SU Schmitz","year":"2016","unstructured":"Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73:2491\u2013509.","journal-title":"Cell Mol Life Sci"},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.3192","volume":"47","author":"MK Iyer","year":"2015","unstructured":"Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199\u2013208.","journal-title":"Nat Genet"},{"key":"1948_CR15","doi-asserted-by":"crossref","unstructured":"Schwarzenbach H, Gahan PB. Circulating non\u2011coding RNAs in recurrent and metastatic ovarian cancer. Cancer Drug Resist. 2019;2(3):399\u2013418.","DOI":"10.20517\/cdr.2019.51"},{"key":"1948_CR16","doi-asserted-by":"crossref","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.","DOI":"10.3389\/fendo.2018.00402"},{"key":"1948_CR17","doi-asserted-by":"crossref","unstructured":"Kim Y\u2011K, Kim B, Kim VN. Re\u2011evaluation of the roles of DROSHA, Exportin\u202f5, and DICER in microRNA biogenesis. Proc Natl Acad Sci USA. 2016;113(13):E1881\u2013E1889.","DOI":"10.1073\/pnas.1602532113"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0092-8674(01)00431-7","volume":"106","author":"A Grishok","year":"2001","unstructured":"Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001;106:23\u201334.","journal-title":"Cell"},{"key":"1948_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","volume":"15","author":"G Meister","year":"2004","unstructured":"Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15:185\u201397.","journal-title":"Mol Cell"},{"key":"1948_CR20","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1007\/s43032-021-00717-w","volume":"29","author":"L Zhao","year":"2022","unstructured":"Zhao L, Liang X, Wang L, Zhang X. The role of miRNA in ovarian cancer: an overview. Reprod Sci. 2022;29:2760\u20137.","journal-title":"Reprod Sci"},{"key":"1948_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23:66.","journal-title":"Mol Cancer"},{"key":"1948_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13048-022-01002-3","volume":"15","author":"A Beg","year":"2022","unstructured":"Beg A, Parveen R, Fouad H, Yahia ME, Hassanein AS. Role of different non-coding RNAs as ovarian cancer biomarkers. J Ovarian Res. 2022;15:72.","journal-title":"J Ovarian Res"},{"key":"1948_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tjog.2014.07.005","volume":"53","author":"A Chao","year":"2014","unstructured":"Chao A, Lai C-H, Chen H-C, Lin C-Y, Tsai C-L, Tang Y-H, et al. Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol. 2014;53:536\u201341.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"1948_CR24","doi-asserted-by":"crossref","unstructured":"Tripathi P, Sachan M, Nara S. Novel ssDNA ligand against ovarian cancer biomarker CA125 with promising diagnostic potential. Front Chem. 2020;8:400","DOI":"10.3389\/fchem.2020.00400"},{"key":"1948_CR25","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.21037\/gs-20-811","volume":"9","author":"R Ji","year":"2020","unstructured":"Ji R, Li Y, He C, Zhu X, He A, Lu Y. Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation. Gland Surg. 2020;9:2175\u201386.","journal-title":"Gland Surg"},{"key":"1948_CR26","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.3390\/cancers12123730","volume":"12","author":"P Charkhchi","year":"2020","unstructured":"Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. Cancers (Basel). 2020;12:3730.","journal-title":"Cancers (Basel)"},{"key":"1948_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ygyno.2013.07.094","volume":"131","author":"B Kristjansdottir","year":"2013","unstructured":"Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013;131:52\u20138.","journal-title":"Gynecol Oncol"},{"key":"1948_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s13277-014-2738-7","volume":"36","author":"H Fujiwara","year":"2015","unstructured":"Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumor Biol. 2015;36:1045\u201353.","journal-title":"Tumor Biol"},{"key":"1948_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/ijms18061207","volume":"18","author":"P-W Choi","year":"2017","unstructured":"Choi P-W, Ng S-W. The functions of MicroRNA-200 family in ovarian cancer: beyond epithelial-mesenchymal transition. Int J Mol Sci. 2017;18:1207.","journal-title":"Int J Mol Sci"},{"key":"1948_CR30","first-page":"2392","volume":"7","author":"Q Cao","year":"2014","unstructured":"Cao Q, Lu K, Dai S, Hu Y, Fan W. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. Int J Clin Exp Pathol. 2014;7:2392\u2013401.","journal-title":"Int J Clin Exp Pathol"},{"key":"1948_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ygyno.2010.12.339","volume":"121","author":"J Chen","year":"2011","unstructured":"Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 2011;121:200\u20135.","journal-title":"Gynecol Oncol"},{"key":"1948_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.18632\/oncotarget.27246","volume":"11","author":"P Ferreira","year":"2020","unstructured":"Ferreira P, Roela RA, Lopez RVM, Del Pilar E-D. The prognostic role of microRNA in epithelial ovarian cancer: a systematic review of literature with an overall survival meta-analysis. Oncotarget. 2020;11:1085\u201395.","journal-title":"Oncotarget"},{"key":"1948_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3892\/or.2020.7895","volume":"45","author":"L Wei","year":"2020","unstructured":"Wei L, He Y, Bi S, Li X, Zhang J, Zhang S. miRNA-199b-3p suppresses growth and progression of ovarian cancer via the CHK1\/E-cadherin\/EMT signaling pathway by targeting ZEB1. Oncol Rep. 2020;45:569\u201381.","journal-title":"Oncol Rep"},{"key":"1948_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13046-018-0906-0","volume":"37","author":"B Wang","year":"2018","unstructured":"Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGF\u03b2 pathway. J Exp Clin Cancer Res. 2018;37:235.","journal-title":"J Exp Clin Cancer Res"},{"key":"1948_CR35","doi-asserted-by":"crossref","unstructured":"Ghafouri\u2011Fard S, Khoshbakht T, Hussen BM, Taheri M, Samadian M. A review on the role of miR\u20111246 in the pathoetiology of different cancers. Front Mol Biosci. 2022;8:771835","DOI":"10.3389\/fmolb.2021.771835"},{"key":"1948_CR36","doi-asserted-by":"publisher","first-page":"19287","DOI":"10.1038\/s41598-023-45317-7","volume":"13","author":"M Niemira","year":"2023","unstructured":"Niemira M, Erol A, Bielska A, Zeller A, Skwarska A, Chwialkowska K, et al. Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer. Sci Rep. 2023;13:19287.","journal-title":"Sci Rep"},{"key":"1948_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13048-018-0477-x","volume":"12","author":"YY Su","year":"2019","unstructured":"Su YY, Sun L, Guo ZR, Li JC, Bai TT, Cai XX, et al. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. J Ovarian Res. 2019;12:6.","journal-title":"J Ovarian Res"},{"key":"1948_CR38","doi-asserted-by":"crossref","unstructured":"Wei J, Lu Y, Wang R, Xu X, Liu Q, He S, Pan H. MicroRNA\u2011375: potential cancer suppressor and therapeutic drug. Biosci Rep. 2021;41(9):BSR20211494.","DOI":"10.1042\/BSR20211494"},{"key":"1948_CR39","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/jog.13053","volume":"42","author":"D Mi","year":"2016","unstructured":"Mi D, Zhang Y, Wang C, Feng Q, Qi P, Chen S. Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. J Obstetrics Gynaecol Res. 2016;42:1326\u201335.","journal-title":"J Obstetrics Gynaecol Res"},{"key":"1948_CR40","doi-asserted-by":"publisher","unstructured":"Gion M, Peloso L, Trevisiol C, Squarcina E, Zappa M, Fabricio ASC. An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study. Clin Chem Lab Med. 2016;54(3):473\u2013482. https:\/\/doi.org\/10.1515\/cclm-2015-0329","DOI":"10.1515\/cclm-2015-0329"},{"key":"1948_CR41","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.2147\/OTT.S137107","volume":"10","author":"O-L Braicu","year":"2017","unstructured":"Braicu O-L, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop L, et al. miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples. Onco Targets Ther. 2017;10:4225\u201338.","journal-title":"Onco Targets Ther"},{"key":"1948_CR42","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3390\/genes13112054","volume":"13","author":"M Davies","year":"2022","unstructured":"Davies M, Davey MG, Miller N. The potential of MicroRNAs as clinical biomarkers to aid ovarian cancer diagnosis and treatment. Genes (Basel). 2022;13:2054.","journal-title":"Genes (Basel)"},{"key":"1948_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nmeth1079","volume":"4","author":"MS Ebert","year":"2007","unstructured":"Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4:721\u20136.","journal-title":"Nat Methods"},{"key":"1948_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12958-021-00860-8","volume":"19","author":"F Yang","year":"2021","unstructured":"Yang F, Tang J, Zhao Z, Zhao C, Xiang Y. Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reprod Biol Endocrinol. 2021;19:178.","journal-title":"Reprod Biol Endocrinol"},{"key":"1948_CR45","doi-asserted-by":"publisher","first-page":"10461","DOI":"10.1038\/s41598-018-28519-2","volume":"8","author":"H Lin","year":"2018","unstructured":"Lin H, Huang Z-P, Liu J, Qiu Y, Tao Y, Wang M, et al. MiR-494-3p promotes PI3K\/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. Sci Rep. 2018;8:10461.","journal-title":"Sci Rep"},{"key":"1948_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omto.2022.03.005","volume":"25","author":"SK Gandham","year":"2022","unstructured":"Gandham SK, Rao M, Shah A, Trivedi MS, Amiji MM. Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer. Mol Ther Oncolytics. 2022;25:57\u201368.","journal-title":"Mol Ther Oncolytics"},{"key":"1948_CR47","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.3390\/cancers13184617","volume":"13","author":"E Chirshev","year":"2021","unstructured":"Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, et al. Let-7i reduces aggressive phenotype and induces BRCAness in ovarian cancer cells. Cancers (Basel). 2021;13:4617.","journal-title":"Cancers (Basel)"},{"key":"1948_CR48","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1535-7163.MCT-19-0510","volume":"19","author":"M Vernon","year":"2020","unstructured":"Vernon M, Lambert B, Meryet-Figui\u00e8re M, Brotin E, Weiswald L-B, Paysant H, et al. Functional miRNA screening identifies wide-ranging antitumor properties of miR-3622b-5p and reveals a new therapeutic combination strategy in ovarian tumor organoids. Mol Cancer Ther. 2020;19:1506\u201319.","journal-title":"Mol Cancer Ther"},{"key":"1948_CR49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s11684-017-0518-7","volume":"11","author":"B Zhou","year":"2017","unstructured":"Zhou B, Xu H, Xia M, Sun C, Li N, Guo E, et al. Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer. Front Med. 2017;11:214\u201322.","journal-title":"Front Med"},{"key":"1948_CR50","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/ncomms3977","volume":"5","author":"A Parikh","year":"2014","unstructured":"Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial\u2013mesenchymal transition. Nat Commun. 2014;5:2977.","journal-title":"Nat Commun"},{"key":"1948_CR51","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41419-018-0946-6","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liu W, Shen F, Ma X, Liu X, Tian F, et al. The activation of microRNA-520h\u2013associated TGF-\u03b21\/c-Myb\/Smad7 axis promotes epithelial ovarian cancer progression. Cell Death Dis. 2018;9:884.","journal-title":"Cell Death Dis"},{"key":"1948_CR52","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3892\/ijo.2015.3121","volume":"47","author":"R Liu","year":"2015","unstructured":"Liu R, Martin TA, Jordan NJ, Ruge F, Ye L, Jiang WG. Metastasis suppressor 1 expression in human ovarian cancer: the impact on cellular migration and metastasis. Int J Oncol. 2015;47:1429\u201339.","journal-title":"Int J Oncol"},{"key":"1948_CR53","doi-asserted-by":"publisher","first-page":"41330","DOI":"10.1038\/srep41330","volume":"7","author":"J Li","year":"2017","unstructured":"Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep. 2017;7:41330.","journal-title":"Sci Rep"},{"key":"1948_CR54","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1038\/cdd.2017.129","volume":"24","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhang X, Tang W, Lin Z, Xu L, Dong R, et al. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-\u03baB in high-grade serous ovarian carcinoma. Cell Death Differ. 2017;24:2089\u2013100.","journal-title":"Cell Death Differ"},{"key":"1948_CR55","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/0008-5472.CAN-17-3014","volume":"78","author":"M Salem","year":"2018","unstructured":"Salem M, O\u2019Brien JA, Bernaudo S, Shawer H, Ye G, Brki\u0107 J, et al. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2\u2013versican pathway. Cancer Res. 2018;78:4175\u201390.","journal-title":"Cancer Res"},{"key":"1948_CR56","doi-asserted-by":"crossref","unstructured":"Chen Z, Zhu J, Zhu Y, Wang J. MicroRNA\u2011616 promotes the progression of ovarian cancer by targeting TIMP2. Oncol Rep. 2018;39(6):2960\u20132968.","DOI":"10.3892\/or.2018.6368"},{"key":"1948_CR57","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1038\/onc.2015.492","volume":"35","author":"R Rupaimoole","year":"2016","unstructured":"Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. 2016;35:4312\u201320.","journal-title":"Oncogene"},{"key":"1948_CR58","doi-asserted-by":"publisher","first-page":"97464","DOI":"10.18632\/oncotarget.22136","volume":"8","author":"M Tang","year":"2017","unstructured":"Tang M, Jiang L, Lin Y, Wu X, Wang K, He Q, et al. Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. Oncotarget. 2017;8:97464\u201375.","journal-title":"Oncotarget"},{"key":"1948_CR59","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-17-0479","volume":"6","author":"J Zhou","year":"2018","unstructured":"Zhou J, Li X, Wu X, Zhang T, Zhu Q, Wang X, et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg\/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol Res. 2018;6:1578\u201392.","journal-title":"Cancer Immunol Res"},{"key":"1948_CR60","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12032-016-0842-9","volume":"33","author":"Z Wei","year":"2016","unstructured":"Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man X, et al. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol. 2016;33:126.","journal-title":"Med Oncol"},{"key":"1948_CR61","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/cmi.2014.30","volume":"11","author":"J Xie","year":"2014","unstructured":"Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S. Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA\/B expression. Cell Mol Immunol. 2014;11:495\u2013502.","journal-title":"Cell Mol Immunol"},{"key":"1948_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13048-019-0589-y","volume":"12","author":"W Zhao","year":"2019","unstructured":"Zhao W, Han T, Li B, Ma Q, Yang P, Li H. miR-552 promotes ovarian cancer progression by regulating PTEN pathway. J Ovarian Res. 2019;12:121.","journal-title":"J Ovarian Res"},{"key":"1948_CR63","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/OTT.S114318","volume":"10","author":"H Liu","year":"2017","unstructured":"Liu H, Pan Y, Han X, Liu J, Li R. MicroRNA-216a promotes the metastasis and epithelial\u2013mesenchymal transition of ovarian cancer by suppressing the PTEN\/AKT pathway. Onco Targets Ther. 2017;10:2701\u20139.","journal-title":"Onco Targets Ther"},{"key":"1948_CR64","doi-asserted-by":"crossref","unstructured":"Han X, Zhang Y, Wang D, Fu X, Li M, Wang A. Upregulation of microRNA\u201118b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer. Oncol Lett. 2017;14(5):5631\u20135637.","DOI":"10.3892\/ol.2017.6854"},{"key":"1948_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.yexcr.2017.07.030","volume":"359","author":"Y Cao","year":"2017","unstructured":"Cao Y, Shi H, Ren F, Jia Y, Zhang R. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Exp Cell Res. 2017;359:185\u201394.","journal-title":"Exp Cell Res"},{"key":"1948_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-018-0870-5","volume":"17","author":"H Liang","year":"2018","unstructured":"Liang H, Yu T, Han Y, Jiang H, Wang C, You T, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 2018;17:119.","journal-title":"Mol Cancer"},{"key":"1948_CR67","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3892\/or.2014.3046","volume":"31","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yan S, Liu X, Zhang W, Li Y, Dong R, et al. miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma. Oncol Rep. 2014;31:1905\u201310.","journal-title":"Oncol Rep"},{"key":"1948_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/path.4443","volume":"235","author":"Y Sun","year":"2015","unstructured":"Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015;235:25\u201336.","journal-title":"J Pathol"},{"key":"1948_CR69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccr.2012.12.020","volume":"23","author":"D Yang","year":"2013","unstructured":"Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master MicroRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:186\u201399.","journal-title":"Cancer Cell"},{"key":"1948_CR70","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3892\/mmr.2017.6956","volume":"16","author":"J Liu","year":"2017","unstructured":"Liu J, Jin S, Wang R. MicroRNA-139 suppressed tumor cell proliferation, migration and invasion by directly targeting HDGF in epithelial ovarian cancer. Mol Med Rep. 2017;16:3379\u201386.","journal-title":"Mol Med Rep"},{"key":"1948_CR71","doi-asserted-by":"crossref","unstructured":"Li C, Yu S, Wu S, Ni Y, Pan Z. MicroRNA-936 targets FGF2 to inhibit epithelial ovarian cancer aggressiveness by deactivating the PI3K\/Akt pathway. Onco Targets Ther. 2019;12:5311\u201322.","DOI":"10.2147\/OTT.S213231"},{"key":"1948_CR72","doi-asserted-by":"publisher","first-page":"12427","DOI":"10.1007\/s13277-014-2560-2","volume":"35","author":"L Wei","year":"2014","unstructured":"Wei L, Liang H, Qin D, Jin H, Zhao Y, She M. MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. Tumor Biol. 2014;35:12427\u201334.","journal-title":"Tumor Biol"},{"key":"1948_CR73","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbrc.2014.05.053","volume":"449","author":"W Wang","year":"2014","unstructured":"Wang W, Ren F, Wu Q, Jiang D, Li H, Peng Z, et al. MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1. Biochem Biophys Res Commun. 2014;449:432\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1948_CR74","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.neo.2018.12.005","volume":"21","author":"G Park Bin","year":"2019","unstructured":"Park Bin G, Kim D. MicroRNA-503\u20135p inhibits the CD97-Mediated JAK2\/STAT3 pathway in metastatic or paclitaxel-resistant ovarian cancer cells. Neoplasia. 2019;21:206\u201315.","journal-title":"Neoplasia"},{"key":"1948_CR75","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41419-019-1604-3","volume":"10","author":"Z Huang","year":"2019","unstructured":"Huang Z, Li Q, Luo K, Zhang Q, Geng J, Zhou X, et al. miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer. Cell Death Dis. 2019;10:372.","journal-title":"Cell Death Dis"},{"key":"1948_CR76","doi-asserted-by":"crossref","unstructured":"Yu R, Cai L, Chi Y, Ding X, Wu X. miR\u2011377 targets CUL4A and regulates metastatic capability in ovarian cancer. Int J Mol Med. 2018;41(6):3147\u20133156.","DOI":"10.3892\/ijmm.2018.3540"},{"key":"1948_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gene.2017.09.012","volume":"637","author":"C Wei","year":"2017","unstructured":"Wei C, Zhang X, He S, Liu B, Han H, Sun X. MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist\/Wnt\/\u03b2-catenin signaling pathway. Gene. 2017;637:25\u201332.","journal-title":"Gene"},{"key":"1948_CR78","doi-asserted-by":"publisher","first-page":"25930","DOI":"10.18632\/oncotarget.8412","volume":"7","author":"Y Pan","year":"2016","unstructured":"Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, et al. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016;7:25930\u201348.","journal-title":"Oncotarget"},{"key":"1948_CR79","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1677\/ERC-09-0203","volume":"17","author":"N Dahiya","year":"2010","unstructured":"Dahiya N, Morin PJ. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer. 2010;17:F77-89.","journal-title":"Endocr Relat Cancer"},{"key":"1948_CR80","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nrneph.2016.51","volume":"12","author":"JM Lorenzen","year":"2016","unstructured":"Lorenzen JM, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol. 2016;12:360\u201373.","journal-title":"Nat Rev Nephrol"},{"key":"1948_CR81","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cell.2010.09.049","volume":"143","author":"D Tian","year":"2010","unstructured":"Tian D, Sun S, Lee JT. The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. Cell. 2010;143:390\u2013403.","journal-title":"Cell"},{"key":"1948_CR82","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10398","volume":"477","author":"M Guttman","year":"2011","unstructured":"Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477:295\u2013300.","journal-title":"Nature"},{"key":"1948_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-genet-110711-155459","volume":"46","author":"G Natoli","year":"2012","unstructured":"Natoli G, Andrau J-C. Noncoding Transcription at enhancers: general principles and functional models. Annu Rev Genet. 2012;46:1\u201319.","journal-title":"Annu Rev Genet"},{"key":"1948_CR84","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384\u20138.","journal-title":"Nature"},{"key":"1948_CR85","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215\u201333.","journal-title":"Cell"},{"key":"1948_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2016.1187322","volume":"3","author":"Z-D Xiao","year":"2016","unstructured":"Xiao Z-D, Liu X, Zhuang L, Gan B. NBR2: A former junk gene emerges as a key player in tumor suppression. Mol Cell Oncol. 2016;3: e1187322.","journal-title":"Mol Cell Oncol"},{"key":"1948_CR87","doi-asserted-by":"crossref","unstructured":"Wang T, Li Z, Yan L, Yan F, Shen H, Tian X. Long non\u2011coding RNA neighbor of BRCA1 gene\u202f2: a crucial regulator in cancer biology. Front Oncol. 2021;11:783526.","DOI":"10.3389\/fonc.2021.783526"},{"key":"1948_CR88","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-023-01765-3","volume":"22","author":"GSR Raju","year":"2023","unstructured":"Raju GSR, Pavitra E, Bandaru SS, Varaprasad GL, Nagaraju GP, Malla RR, et al. HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer. Mol Cancer. 2023;22:65.","journal-title":"Mol Cancer"},{"key":"1948_CR89","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1159\/000490131","volume":"47","author":"Q Tang","year":"2018","unstructured":"Tang Q, Hann SS. HOTAIR: an oncogenic long non-coding RNA in human cancer. Cell Physiol Biochem. 2018;47:893\u2013913.","journal-title":"Cell Physiol Biochem"},{"key":"1948_CR90","doi-asserted-by":"crossref","unstructured":"Duan Y, Chen J, Yang Y, Qu Z, Lu Y, Sun D. LncRNA HOTAIR contributes Taxol\u2011resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down\u2011regulating miR\u201134a. Biosci Rep. 2020;40(7):BSR20201627","DOI":"10.1042\/BSR20201627"},{"key":"1948_CR91","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12967-020-02320-0","volume":"18","author":"H Mozdarani","year":"2020","unstructured":"Mozdarani H, Ezzatizadeh V, Rahbar PR. The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment. J Transl Med. 2020;18:152.","journal-title":"J Transl Med"},{"key":"1948_CR92","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1096\/fj.10-172452","volume":"25","author":"E Pasmant","year":"2011","unstructured":"Pasmant E, Sabbagh A, Vidaud M, Bi\u00e8che I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011;25:444\u20138.","journal-title":"FASEB J"},{"key":"1948_CR93","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nsmb.1824","volume":"17","author":"M-A El","year":"2010","unstructured":"El M-A, Nicholls J, Maertens GN, Brookes S, Bernstein E, Peters G. Role for the MOV10 RNA helicase in Polycomb-mediated repression of the INK4a tumor suppressor. Nat Struct Mol Biol. 2010;17:862\u20138.","journal-title":"Nat Struct Mol Biol"},{"key":"1948_CR94","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.3892\/ijo.2015.2943","volume":"46","author":"J-J Qiu","year":"2025","unstructured":"Qiu J-J, Lin Y-Y, Ding J-X, Feng W-W, Jin H-Y, Hua K-Q. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion\/metastasis in serous ovarian cancer. Int J Oncol. 2025;46:2497\u2013505.","journal-title":"Int J Oncol"},{"key":"1948_CR95","doi-asserted-by":"publisher","first-page":"32478","DOI":"10.18632\/oncotarget.8744","volume":"7","author":"J Qiu","year":"2016","unstructured":"Qiu J, Wang Y, Liu Y, Zhang Y, Ding J, Hua K. The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer. Oncotarget. 2016;7:32478\u201392.","journal-title":"Oncotarget"},{"key":"1948_CR96","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40364-020-00221-4","volume":"8","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Xiao T, Ou W, Wu Z, Wu J, Tang J, et al. LncRNA SNHG16 as a potential biomarker and therapeutic target in human cancers. Biomark Res. 2020;8:41.","journal-title":"Biomark Res"},{"key":"1948_CR97","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1186\/s12885-024-12969-1","volume":"24","author":"T Shuang","year":"2024","unstructured":"Shuang T, Wu S, Zhao Y, Yang Y, Pei M. The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian cancer cells. BMC Cancer. 2024;24:1213.","journal-title":"BMC Cancer"},{"key":"1948_CR98","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.gendis.2022.04.007","volume":"9","author":"J Li","year":"2022","unstructured":"Li J, Ming Z, Yang L, Wang T, Liu G, Ma Q. Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities. Genes Dis. 2022;9:1478\u201392.","journal-title":"Genes Dis"},{"key":"1948_CR99","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1038\/sj.onc.1207808","volume":"23","author":"T Kawakami","year":"2004","unstructured":"Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, Sugihara H, et al. Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene. 2004;23:6163\u20139.","journal-title":"Oncogene"},{"key":"1948_CR100","first-page":"769","volume":"1","author":"K-C Huang","year":"2002","unstructured":"Huang K-C, Rao PH, Lau CC, Heard E, Ng S-K, Brown C, et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002;1:769\u201376.","journal-title":"Mol Cancer Ther"},{"key":"1948_CR101","doi-asserted-by":"publisher","first-page":"44719","DOI":"10.18632\/oncotarget.8089","volume":"7","author":"M Meryet-Figui\u00e8re","year":"2016","unstructured":"Meryet-Figui\u00e8re M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, et al. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016;7:44719\u201334.","journal-title":"Oncotarget"},{"key":"1948_CR102","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-018-0793-4","volume":"37","author":"L Zhan","year":"2018","unstructured":"Zhan L, Li J, Wei B. Long non-coding RNAs in ovarian cancer. J Exp Clin Cancer Res. 2018;37:120.","journal-title":"J Exp Clin Cancer Res"},{"key":"1948_CR103","doi-asserted-by":"publisher","first-page":"38983","DOI":"10.1038\/srep38983","volume":"6","author":"H Wang","year":"2016","unstructured":"Wang H, Fu Z, Dai C, Cao J, Liu X, Xu J, et al. LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep. 2016;6:38983.","journal-title":"Sci Rep"},{"key":"1948_CR104","doi-asserted-by":"crossref","unstructured":"Xia X, Li Z, Li Y, Ye F, Zhou X. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR\u2011506\u20113p\/FOXP1 axis. J Gynecol Oncol. 2022;33(6):e81.","DOI":"10.3802\/jgo.2022.33.e81"},{"key":"1948_CR105","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/gcc.20356","volume":"45","author":"A Staebler","year":"2006","unstructured":"Staebler A, Karberg B, Behm J, Kuhlmann P, Neubert U, Schmidt H, et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer. 2006;45:905\u201317.","journal-title":"Genes Chromosomes Cancer"},{"key":"1948_CR106","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-13-0066","volume":"19","author":"J George","year":"2013","unstructured":"George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res. 2013;19:3474\u201384.","journal-title":"Clin Cancer Res"},{"key":"1948_CR107","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-06-2882","volume":"13","author":"Y Guan","year":"2007","unstructured":"Guan Y, Kuo W-L, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007;13:5745\u201355.","journal-title":"Clin Cancer Res"},{"key":"1948_CR108","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1755-8794-2-21","volume":"2","author":"PM Haverty","year":"2009","unstructured":"Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics. 2009;2:21.","journal-title":"BMC Med Genomics"},{"key":"1948_CR109","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1158\/1078-0432.CCR-16-1402","volume":"23","author":"P Martini","year":"2017","unstructured":"Martini P, Paracchini L, Caratti G, Mello-Grand M, Fruscio R, Beltrame L, et al. lncRNAs as novel indicators of patients\u2019 prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study. Clin Cancer Res. 2017;23:2356\u201366.","journal-title":"Clin Cancer Res"},{"key":"1948_CR110","doi-asserted-by":"publisher","first-page":"238","DOI":"10.20892\/j.issn.2095-3941.2017.0174","volume":"15","author":"C Ying","year":"2018","unstructured":"Ying C, Hui D, Lewen B, Wenxin L. LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214. Cancer Biol Med. 2018;15:238.","journal-title":"Cancer Biol Med"},{"key":"1948_CR111","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.3390\/ijms24076392","volume":"24","author":"M Stevanovic","year":"2023","unstructured":"Stevanovic M, Kovacevic-Grujicic N, Petrovic I, Drakulic D, Milivojevic M, Mojsin M. Crosstalk between SOX genes and long non-coding RNAs in Glioblastoma. Int J Mol Sci. 2023;24:6392.","journal-title":"Int J Mol Sci"},{"key":"1948_CR112","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41419-020-03358-0","volume":"12","author":"R Jiang","year":"2021","unstructured":"Jiang R, Zhang H, Zhou J, Wang J, Xu Y, Zhang H, et al. Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression. Cell Death Dis. 2021;12:145.","journal-title":"Cell Death Dis"},{"key":"1948_CR113","doi-asserted-by":"crossref","unstructured":"Wang K, Zhao Y, Wang Y-M. LncRNA MALAT1 promotes survival of epithelial ovarian cancer cells by downregulating miR-145-5p. Cancer Manag Res. 2020;12:11359\u201369.","DOI":"10.2147\/CMAR.S267355"},{"key":"1948_CR114","first-page":"77","volume":"26","author":"F Bossaghzadeh","year":"2022","unstructured":"Bossaghzadeh F, Hajjari M, Sheikhi A, Salahshourifar I, Irani S. HOTAIR induces the downregulation of miR-200 family members in gastric cancer cell lines. Iran Biomed J. 2022;26:77\u201384.","journal-title":"Iran Biomed J"},{"key":"1948_CR115","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/or.2021.7990","volume":"45","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhou K, Zhang X, Wu C, Deng D, Yao Z. Roles of the H19\/microRNA-675 axis in the proliferation and epithelial-mesenchymal transition of human cutaneous squamous cell carcinoma cells. Oncol Rep. 2021;45:39.","journal-title":"Oncol Rep"},{"key":"1948_CR116","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3724\/abbs.2021022","volume":"54","author":"H Zhou","year":"2022","unstructured":"Zhou H, Wang Y, Liu Z, Zhang Z, Xiong L, Wen Y. Recent advances of NEAT1-miRNA interactions in cancer. Acta Biochim Biophys Sin (Shanghai). 2022;54:153\u201362.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"1948_CR117","doi-asserted-by":"crossref","unstructured":"Tan X, Shao Y, Teng Y, Liu S, Li W, Xue L, et al. The cancer\u2011testis long non\u2011coding RNA PCAT6 facilitates the malignant phenotype of ovarian cancer by sponging miR\u2011143\u20113p. Front Cell Dev Biol. 2021;9:593677.","DOI":"10.3389\/fcell.2021.593677"},{"key":"1948_CR118","doi-asserted-by":"crossref","unstructured":"Guo Y, Sun Z, Chen M, Lun J. LncRNA TUG1 regulates proliferation of cardiac fibroblast via the miR\u201129b\u20113p\/TGF\u2011\u03b21 axis. Front Cardiovasc Med. 2021;8:646806.","DOI":"10.3389\/fcvm.2021.646806"},{"key":"1948_CR119","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/15476286.2019.1702283","volume":"17","author":"S Oncul","year":"2020","unstructured":"Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol. 2020;17:1523\u201334.","journal-title":"RNA Biol"},{"key":"1948_CR120","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-017-0630-y","volume":"16","author":"J Liu","year":"2017","unstructured":"Liu J, Liu T, Wang X, He A. Circles reshaping the RNA world: from waste to treasure. Mol Cancer. 2017;16:58.","journal-title":"Mol Cancer"},{"key":"1948_CR121","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2890","volume":"32","author":"WR Jeck","year":"2014","unstructured":"Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453\u201361.","journal-title":"Nat Biotechnol"},{"key":"1948_CR122","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","volume":"495","author":"S Memczak","year":"2013","unstructured":"Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333\u20138.","journal-title":"Nature"},{"key":"1948_CR123","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.3390\/cancers14225711","volume":"14","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, Chen Y, Agbede O, Eshaghi E, Peng C. Circular RNAs in epithelial ovarian cancer: from biomarkers to therapeutic targets. Cancers (Basel). 2022;14:5711.","journal-title":"Cancers (Basel)"},{"key":"1948_CR124","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biocel.2019.04.011","volume":"112","author":"F Teng","year":"2019","unstructured":"Teng F, Xu J, Zhang M, Liu S, Gu Y, Zhang M, et al. Comprehensive circular RNA expression profiles and the tumor-suppressive function of circHIPK3 in ovarian cancer. Int J Biochem Cell Biol. 2019;112:8\u201317.","journal-title":"Int J Biochem Cell Biol"},{"key":"1948_CR125","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/2211536607666180525102330","volume":"7","author":"A Conte","year":"2018","unstructured":"Conte A, Pierantoni GM. Update on the regulation of HIPK1, HIPK2 and HIPK3 protein kinases by microRNAs. MicroRNA. 2018;7:178\u201386.","journal-title":"MicroRNA"},{"key":"1948_CR126","first-page":"3713","volume":"22","author":"N Liu","year":"2018","unstructured":"Liu N, Zhang J, Zhang L-Y, Wang L. CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2018;22:3713\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1948_CR127","doi-asserted-by":"crossref","unstructured":"Ning L, Long B, Zhang W, Yu M, Wang S, Cao D, et al. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. Int J Oncol. 2018;53(6):2637\u20132646.","DOI":"10.3892\/ijo.2018.4566"},{"key":"1948_CR128","doi-asserted-by":"crossref","unstructured":"Luo Y, Gui R. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells. J Gynecol Oncol. 2020;31(5):e75.","DOI":"10.3802\/jgo.2020.31.e75"},{"key":"1948_CR129","doi-asserted-by":"crossref","unstructured":"Wang W, Wang J, Zhang X, Liu G. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer. Onco Targets Ther. 2019;12:7451\u20137.","DOI":"10.2147\/OTT.S220700"},{"key":"1948_CR130","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5582\/bst.2019.01021","volume":"13","author":"Y Gao","year":"2019","unstructured":"Gao Y, Zhang C, Liu Y, Wang M. Circular RNA profiling reveals circRNA1656 as a novel biomarker in high grade serous ovarian cancer. Biosci Trends. 2019;13:204\u201311.","journal-title":"Biosci Trends"},{"key":"1948_CR131","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13048-022-00988-0","volume":"15","author":"L Ge","year":"2022","unstructured":"Ge L, Sun Y, Shi Y, Liu G, Teng F, Geng Z, et al. Plasma circRNA microarray profiling identifies novel circRNA biomarkers for the diagnosis of ovarian cancer. J Ovarian Res. 2022;15:58.","journal-title":"J Ovarian Res"},{"key":"1948_CR132","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13048-020-00664-1","volume":"13","author":"N Zhang","year":"2020","unstructured":"Zhang N, Jin Y, Hu Q, Cheng S, Wang C, Yang Z, et al. Circular RNA hsa_circ_0078607 suppresses ovarian cancer progression by regulating miR-518a-5p\/Fas signaling pathway. J Ovarian Res. 2020;13:64.","journal-title":"J Ovarian Res"},{"key":"1948_CR133","doi-asserted-by":"crossref","unstructured":"Hu Y, Zhu Y, Zhang W, Lang J, Ning L. Utility of plasma circBNC2 as a diagnostic biomarker in epithelial ovarian cancer. Onco Targets Ther. 2019;12:9715\u201323.","DOI":"10.2147\/OTT.S211413"},{"key":"1948_CR134","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12885-021-09073-z","volume":"22","author":"L Ning","year":"2022","unstructured":"Ning L, Lang J, Wu L. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer. BMC Cancer. 2022;22:6.","journal-title":"BMC Cancer"},{"key":"1948_CR135","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-022-01611-y","volume":"21","author":"M Wu","year":"2022","unstructured":"Wu M, Qiu Q, Zhou Q, Li J, Yang J, Zheng C, et al. circFBXO7\/miR-96-5p\/MTSS1 axis is an important regulator in the Wnt signaling pathway in ovarian cancer. Mol Cancer. 2022;21:137.","journal-title":"Mol Cancer"},{"key":"1948_CR136","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13048-022-00979-1","volume":"15","author":"Y Fu","year":"2022","unstructured":"Fu Y, Sun H. The molecular mechanism of circRHOBTB3 inhibits the proliferation and invasion of epithelial ovarian cancer by serving as the ceRNA of miR-23a-3p. J Ovarian Res. 2022;15:66.","journal-title":"J Ovarian Res"},{"key":"1948_CR137","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/OTT.S266186","volume":"14","author":"X Wu","year":"2021","unstructured":"Wu X, Liu D, Wang S, Liu J. Circ_0007444 inhibits the progression of ovarian cancer via mediating the miR-570-3p\/PTEN axis. Onco Targets Ther. 2021;14:97\u2013110.","journal-title":"Onco Targets Ther"},{"key":"1948_CR138","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12943-022-01531-x","volume":"21","author":"X Chong","year":"2022","unstructured":"Chong X, Chen J, Zheng N, Zhou Z, Hai Y, Chen S, et al. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Mol Cancer. 2022;21:118.","journal-title":"Mol Cancer"},{"key":"1948_CR139","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.7150\/thno.72471","volume":"12","author":"H Zhou","year":"2022","unstructured":"Zhou H, Du Y, Wei X, Song C, Song J, Xu N, et al. DDX56 transcriptionally activates MIST1 to facilitate tumorigenesis of HCC through PTEN-AKT signaling. Theranostics. 2022;12:6069\u201387.","journal-title":"Theranostics"},{"key":"1948_CR140","doi-asserted-by":"crossref","unstructured":"Chen H, Mao M, Jiang J, Zhu D, Li P. Circular RNA CDR1as acts as a sponge of miR-135b-5p to suppress ovarian cancer progression. Onco Targets Ther. 2019;12:3869\u201379.","DOI":"10.2147\/OTT.S207938"},{"issue":"22","key":"1948_CR141","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.3390\/cancers14225711","volume":"14","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, et al. Circular RNAs in epithelial ovarian cancer: from biomarkers to therapeutic targets. Cancers (Basel). 2022;14(22):5711.","journal-title":"Cancers (Basel)"},{"key":"1948_CR142","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13048-021-00916-8","volume":"14","author":"S Sun","year":"2021","unstructured":"Sun S, Fang H. Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3\/miR-320a\/SMG1 axis. J Ovarian Res. 2021;14:158.","journal-title":"J Ovarian Res"},{"key":"1948_CR143","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-019-1080-5","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhou Q, Qiu Q, Hou L, Wu M, Li J, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9\/BRCA1\/DNAJB6\/KLF4\/AKT1 axis in ovarian cancer. Mol Cancer. 2019;18:144.","journal-title":"Mol Cancer"},{"key":"1948_CR144","doi-asserted-by":"publisher","first-page":"19095","DOI":"10.18632\/aging.103706","volume":"12","author":"X Wang","year":"2020","unstructured":"Wang X, Yao Y, Jin M. Circ-0001068 is a novel biomarker for ovarian cancer and inducer of PD1 expression in T cells. Aging. 2020;12:19095\u2013106.","journal-title":"Aging"},{"key":"1948_CR145","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbrc.2018.09.060","volume":"505","author":"J Hu","year":"2018","unstructured":"Hu J, Wang L, Chen J, Gao H, Zhao W, Huang Y, et al. The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145\/RASA1 signaling. Biochem Biophys Res Commun. 2018;505:222\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1948_CR146","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12935-020-01420-7","volume":"20","author":"C Lin","year":"2020","unstructured":"Lin C, Xu X, Yang Q, Liang L, Qiao S. Circular RNA ITCH suppresses proliferation, invasion, and glycolysis of ovarian cancer cells by up-regulating CDH1 via sponging miR-106a. Cancer Cell Int. 2020;20:336.","journal-title":"Cancer Cell Int"},{"key":"1948_CR147","first-page":"7283","volume":"23","author":"M Sheng","year":"2019","unstructured":"Sheng M, Wei N, Yang H-Y, Yan M, Zhao Q-X, Jing L-J. CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144. Eur Rev Med Pharmacol Sci. 2019;23:7283\u201394.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1948_CR148","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13048-020-00685-w","volume":"13","author":"Q Xu","year":"2020","unstructured":"Xu Q, Deng B, Li M, Chen Y, Zhuan L. circRNA-UBAP2 promotes the proliferation and inhibits apoptosis of ovarian cancer though miR-382-5p\/PRPF8 axis. J Ovarian Res. 2020;13:81.","journal-title":"J Ovarian Res"},{"key":"1948_CR149","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13046-019-1437-z","volume":"38","author":"Z-H Zong","year":"2019","unstructured":"Zong Z-H, Du Y-P, Guan X, Chen S, Zhao Y. CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182. J Exp Clin Cancer Res. 2019;38:437.","journal-title":"J Exp Clin Cancer Res"},{"key":"1948_CR150","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.omtn.2019.09.032","volume":"18","author":"X Guan","year":"2019","unstructured":"Guan X, Zong Z, Liu Y, Chen S, Wang L, Zhao Y. circPUM1 promotes tumorigenesis and progression of ovarian cancer by sponging miR-615-5p and miR-6753-5p. Mol Ther Nucleic Acids. 2019;18:882\u201392.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1948_CR151","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7150\/jca.35041","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Lin S, Mo Z, Jiang J, Tang H, Wu C, et al. CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228\/p53\/epithelial-mesenchymal transition (EMT) axis. J Cancer. 2020;11:599\u2013609.","journal-title":"J Cancer"},{"key":"1948_CR152","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-020-01163-z","volume":"19","author":"X Gan","year":"2020","unstructured":"Gan X, Zhu H, Jiang X, Obiegbusi SC, Yong M, Long X, et al. CircMUC16 promotes autophagy of epithelial ovarian cancer via interaction with ATG13 and miR-199a. Mol Cancer. 2020;19:45.","journal-title":"Mol Cancer"},{"key":"1948_CR153","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbrc.2020.03.024","volume":"526","author":"F Xu","year":"2020","unstructured":"Xu F, Ni M, Li J, Cheng J, Zhao H, Zhao J, et al. Circ0004390 promotes cell proliferation through sponging miR-198 in ovarian cancer. Biochem Biophys Res Commun. 2020;526:14\u201320.","journal-title":"Biochem Biophys Res Commun"},{"key":"1948_CR154","doi-asserted-by":"crossref","unstructured":"Wang G, Zhang H, Li P. Upregulation of hsa_circRNA_102958 indicates poor prognosis and promotes ovarian cancer progression through miR-1205\/SH2D3A axis. Cancer Manag Res. 2020;12:4045\u201353.","DOI":"10.2147\/CMAR.S248560"},{"key":"1948_CR155","doi-asserted-by":"publisher","first-page":"14080","DOI":"10.18632\/aging.103388","volume":"12","author":"J Zhou","year":"2020","unstructured":"Zhou J, Dong Z-N, Qiu B-Q, Hu M, Liang X-Q, Dai X, et al. CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p\/E2F1 axis. Aging. 2020;12:14080\u201391.","journal-title":"Aging"},{"key":"1948_CR156","doi-asserted-by":"publisher","first-page":"14314","DOI":"10.18632\/aging.103470","volume":"12","author":"J Gong","year":"2020","unstructured":"Gong J, Xu X, Zhang X, Zhou Y. Circular RNA-9119 suppresses in ovarian cancer cell viability via targeting the microRNA-21-5p\u2013PTEN\u2013Akt pathway. Aging. 2020;12:14314\u201328.","journal-title":"Aging"},{"key":"1948_CR157","doi-asserted-by":"publisher","first-page":"17209","DOI":"10.18632\/aging.103668","volume":"12","author":"J Ding","year":"2020","unstructured":"Ding J, Wang Q, Guo N, Wang H, Chen H, Ni G, et al. CircRNA circ_0072995 promotes the progression of epithelial ovarian cancer by modulating miR-147a\/CDK6 axis. Aging. 2020;12:17209\u201323.","journal-title":"Aging"},{"key":"1948_CR158","doi-asserted-by":"crossref","unstructured":"An Q, Liu T, Wang M, Yang Y, Zhang Z, Lin Z, et al. circKRT7-miR-29a-3p-COL1A1 axis promotes ovarian cancer cell progression. Onco Targets Ther. 2020;13:8963\u201376.","DOI":"10.2147\/OTT.S259033"},{"key":"1948_CR159","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7150\/jca.52234","volume":"12","author":"M Li","year":"2021","unstructured":"Li M, Chi C, Zhou L, Chen Y, Tang X. Circular PVT1 regulates cell proliferation and invasion via miR-149-5p\/FOXM1 axis in ovarian cancer. J Cancer. 2021;12:611\u201321.","journal-title":"J Cancer"},{"key":"1948_CR160","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41419-021-03486-1","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhu H, Hu J. CircRAB11FIP1 promoted autophagy flux of ovarian cancer through DSC1 and miR-129. Cell Death Dis. 2021;12:219.","journal-title":"Cell Death Dis"},{"key":"1948_CR161","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12935-021-01985-x","volume":"21","author":"S-G Wu","year":"2021","unstructured":"Wu S-G, Zhou P, Chen J-X, Lei J, Hua L, Dong Y, et al. circ-PTK2 (hsa_circ_0008305) regulates the pathogenic processes of ovarian cancer via miR-639 and FOXC1 regulatory cascade. Cancer Cell Int. 2021;21:277.","journal-title":"Cancer Cell Int"},{"key":"1948_CR162","doi-asserted-by":"publisher","first-page":"19072","DOI":"10.1007\/s11356-021-13710-2","volume":"29","author":"H Wang","year":"2022","unstructured":"Wang H, Zhang X, Qiao L, Wang H. CircRNA circ_0000554 promotes ovarian cancer invasion and proliferation by regulating miR-567. Environ Sci Pollut Res. 2022;29:19072\u201380.","journal-title":"Environ Sci Pollut Res"},{"key":"1948_CR163","doi-asserted-by":"crossref","unstructured":"Lyu M, Li X, Shen Y, Lu J, Zhang L, Zhong S, et al. CircATRNL1 and circZNF608 inhibit ovarian cancer by sequestering miR\u2011152\u20115p and encoding protein. Front Genet. 2022;13:784089.","DOI":"10.3389\/fgene.2022.784089"},{"key":"1948_CR164","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10528-022-10227-2","volume":"60","author":"X Li","year":"2022","unstructured":"Li X, Jiang X, Lu J, Lin Y, Jiang L, Li Y, et al. CircCERS6 suppresses the development of epithelial ovarian cancer through mediating miR-630\/RASSF8. Biochem Genet. 2022;60:2611\u201329.","journal-title":"Biochem Genet"},{"key":"1948_CR165","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13048-022-01025-w","volume":"15","author":"T Liu","year":"2022","unstructured":"Liu T, Yuan L, Zou X. Circular RNA circ-BNC2 (hsa_circ_0008732) inhibits the progression of ovarian cancer through microRNA-223-3p\/ FBXW7 axis. J Ovarian Res. 2022;15:95.","journal-title":"J Ovarian Res"},{"key":"1948_CR166","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1002\/cam4.5317","volume":"12","author":"Y Wu","year":"2023","unstructured":"Wu Y, Zhou J, Li Y, Shi X, Shen F, Chen M, et al. Hsa_circ_0001445 works as a cancer suppressor via miR-576-5p\/SFRP1 axis regulation in ovarian cancer. Cancer Med. 2023;12:5736\u201350.","journal-title":"Cancer Med"},{"key":"1948_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.repbio.2022.100702","volume":"22","author":"Y Pan","year":"2022","unstructured":"Pan Y, Huang Q, Peng X, Yu S, Liu N. Circ_0015756 promotes ovarian cancer progression via the miR-145\u20135p\/PSAT1 axis. Reprod Biol. 2022;22: 100702.","journal-title":"Reprod Biol"},{"key":"1948_CR168","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/2326-6066.CIR-22-0410","volume":"11","author":"F Wang","year":"2023","unstructured":"Wang F, Niu Y, Chen K, Yuan X, Qin Y, Zheng F, et al. Extracellular vesicle-packaged circATP2B4 mediates M2 macrophage polarization via miR-532-3p\/SREBF1 axis to promote epithelial ovarian cancer metastasis. Cancer Immunol Res. 2023;11:199\u2013216.","journal-title":"Cancer Immunol Res"},{"key":"1948_CR169","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10985549.2022.2160605","volume":"43","author":"X Chen","year":"2023","unstructured":"Chen X, Ren XEJ, Zhou Y, Bian R. Exosome-transmitted circ IFNGR2 modulates ovarian cancer metastasis via miR-378\/ST5 axis. Mol Cell Biol. 2023;43:22\u201342.","journal-title":"Mol Cell Biol"},{"key":"1948_CR170","doi-asserted-by":"crossref","unstructured":"Song R, Chai T, Liu J, Chu A, Sun C, Liu Z, et al. Knockdown of circMFN2 inhibits cell progression and glycolysis by miR\u2011198\/CUL4B pathway in ovarian cancer. J Biochem Mol Toxicol. 2023;37(8):e23383.","DOI":"10.1002\/jbt.23383"},{"key":"1948_CR171","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s12033-023-00773-4","volume":"66","author":"H Wang","year":"2024","unstructured":"Wang H, Liang C, Lin J, Dong Y, Wang Y, Xia L. Hsa_circ_0001741 Suppresses ovarian cancer cell proliferations through adsorption of miR-188-5p and promotion of FOXN2 expression. Mol Biotechnol. 2024;66:1477\u201383.","journal-title":"Mol Biotechnol"},{"key":"1948_CR172","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13048-023-01170-w","volume":"16","author":"H Wang","year":"2023","unstructured":"Wang H, Lan S, Wang L, Zhao J, Jia X, Xu J, et al. Expression of circ-PHC3 enhances ovarian cancer progression via regulation of the miR-497-5p\/SOX9 pathway. J Ovarian Res. 2023;16:142.","journal-title":"J Ovarian Res"},{"key":"1948_CR173","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","volume":"13","author":"W Tian","year":"2022","unstructured":"Tian W, Lei N, Zhou J, Chen M, Guo R, Qin B, et al. Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death Dis. 2022;13:64.","journal-title":"Cell Death Dis"},{"key":"1948_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2018.12.045","volume":"86","author":"W Liao","year":"2019","unstructured":"Liao W, Du Y, Zhang C, Pan F, Yao Y, Zhang T, et al. Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy. Acta Biomater. 2019;86:1\u201314.","journal-title":"Acta Biomater"},{"key":"1948_CR175","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1479-5876-12-4","volume":"12","author":"M Kobayashi","year":"2014","unstructured":"Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med. 2014;12:4.","journal-title":"J Transl Med"},{"key":"1948_CR176","first-page":"53","volume":"1","author":"M Bullock","year":"2015","unstructured":"Bullock M, Silva A, Kanlikilicer-Unaldi P, Filant J, Rashed M, Sood A, et al. Exosomal non-coding RNAs: diagnostic, prognostic and therapeutic applications in cancer. Noncoding RNA. 2015;1:53\u201368.","journal-title":"Noncoding RNA"},{"key":"1948_CR177","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13048-018-0458-0","volume":"11","author":"M Kobayashi","year":"2018","unstructured":"Kobayashi M, Sawada K, Nakamura K, Yoshimura A, Miyamoto M, Shimizu A, et al. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. J Ovarian Res. 2018;11:81.","journal-title":"J Ovarian Res"},{"key":"1948_CR178","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.7150\/ijbs.28048","volume":"14","author":"J-J Qiu","year":"2018","unstructured":"Qiu J-J, Lin X-J, Tang X-Y, Zheng T-T, Lin Y-Y, Hua K-Q. Exosomal metastasis-associated lung adenocarcinoma transcript 1 Promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci. 2018;14:1960\u201373.","journal-title":"Int J Biol Sci"},{"key":"1948_CR179","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wei Y\u2011J, Zhang Y\u2011F, Liu H\u2011W, Zhang Y\u2011F. Emerging functions and clinical applications of exosomal ncRNAs in ovarian cancer. Front Oncol. 2021;11:765458.","DOI":"10.3389\/fonc.2021.765458"},{"key":"1948_CR180","doi-asserted-by":"publisher","first-page":"11150","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, Co N-N, Tsuruga T, Yeung T-L, Kwan S-Y, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150.","journal-title":"Nat Commun"},{"key":"1948_CR181","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3892\/ijmm.2020.4634","volume":"46","author":"L Qiu","year":"2020","unstructured":"Qiu L, Wang J, Chen M, Chen F, Tu W. Exosomal microRNA-146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2-mediated PI3K\/Akt axis. Int J Mol Med. 2020;46:609\u201320.","journal-title":"Int J Mol Med"},{"key":"1948_CR182","doi-asserted-by":"publisher","unstructured":"Wang J, Wang C, Li Y, Li M, Zhu T, Shen Z, et al. Potential of peptide\u2011engineered exosomes with overexpressed miR\u201192b\u20113p in anti\u2011angiogenic therapy of ovarian cancer. Clin Transl Med. 2021;11(5):e425. https:\/\/doi.org\/10.1002\/ctm2.425","DOI":"10.1002\/ctm2.425"},{"key":"1948_CR183","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2022.01.011","volume":"530","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Shuang T, Gao Y, Lu F, Zhang J, He W, et al. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization. Cancer Lett. 2022;530:45\u201358.","journal-title":"Cancer Lett"},{"key":"1948_CR184","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12935-022-02602-1","volume":"22","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Khoshbakht T, Hussen BM, Taheri M, Samsami M. Emerging role of circular RNAs in the pathogenesis of ovarian cancer. Cancer Cell Int. 2022;22:172.","journal-title":"Cancer Cell Int"},{"key":"1948_CR185","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/15476286.2017.1391443","volume":"15","author":"J Yang","year":"2018","unstructured":"Yang J, Meng X, Pan J, Jiang N, Zhou C, Wu Z, et al. CRISPR\/Cas9-mediated noncoding RNA editing in human cancers. RNA Biol. 2018;15:35\u201343.","journal-title":"RNA Biol"},{"key":"1948_CR186","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1535-7163.MCT-23-0314","volume":"23","author":"W Wang","year":"2024","unstructured":"Wang W, Zhou Y, Wang J, Zhang S, Ozes A, Gao H, et al. Targeting ovarian cancer stem cells by dual inhibition of the long noncoding RNA HOTAIR and lysine methyltransferase EZH2. Mol Cancer Ther. 2024;23:1666\u201379.","journal-title":"Mol Cancer Ther"},{"key":"1948_CR187","doi-asserted-by":"crossref","unstructured":"Qin M, Zhang C, Li Y. Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance. Front Pharmacol. 2023;14:1194719.","DOI":"10.3389\/fphar.2023.1194719"},{"key":"1948_CR188","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics \u2014 challenges and potential solutions. Nat Rev Drug Discov. 2021;20:629\u201351.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-01948-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-025-01948-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-01948-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:04:25Z","timestamp":1758128665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-025-01948-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":188,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1007\/s43032-025-01948-x","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest, financial or otherwise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}